Description

Product Information

• Product Name: Olanib 150 mg
• Generic Name: Olaparib
• Manufacturer: Everest Pharmaceuticals Ltd

Indications

• Ovarian Cancer: Maintenance therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Breast Cancer: Treatment of HER2-negative metastatic breast cancer with a germline BRCA mutation
• Pancreatic Cancer: Treatment of metastatic pancreatic cancer with a germline BRCA mutation, previously treated with platinum-based chemotherapy
• Prostate Cancer: Treatment of metastatic castration-resistant prostate cancer with germline or somatic HRR gene mutations, including BRCA1 and BRCA2

Dosage

• Recommended Dose: 300 mg (two 150 mg tablets) twice a day, for a total daily dose of 600 mg
• Duration: Treatment should continue until disease progression or unacceptable side effects occur

Packaging

• Container Type: HDPE
• Number of Tablets: 120 tablets per container
• Tablet Strength: Each tablet contains 150 mg of Olaparib

Usage

• Administration: The tablets should be taken orally with water
• Timing: The recommended dosing schedule is twice a day, at approximately 12-hour intervals

Important Notes

• Contraindications: Olanib 150 mg is contraindicated in patients with severe renal impairment or severe hepatic impairment
• Warnings: Patients should be monitored for signs of myelosuppression, gastrointestinal toxicity, and other adverse reactions
  

  Key Benefits

  • Indicated for the treatment of certain types of advanced cancers, including:
    • Maintenance therapy for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • Treatment of HER2-negative metastatic breast cancer with a germline BRCA mutation
    • Treatment of metastatic pancreatic cancer with a germline BRCA mutation
    • Treatment of metastatic castration-resistant prostate cancer with germline or somatic HRR gene mutations
  • Helps inhibit the activity of PARP enzymes, which are involved in DNA repair, leading to cancer cell death

  Key Ingredients

  • Active Ingredient: Olaparib 150 mg
  • Olaparib is a PARP (Poly (ADP-ribose) polymerase) inhibitor that works by blocking the activity of PARP enzymes, which are involved in DNA repair in cancer cells
  • This disrupts the ability of cancer cells to repair their DNA, leading to cell death

  Olanib (olaparib) has the potential to interact with several other medications:

  Drugs that May Decrease Olaparib Plasma Concentrations

  Avoid concomitant use of strong CYP3A inducers, as they can decrease olaparib plasma concentrations. Examples include:

  • Phenytoin
  • Rifampicin
  • Carbamazepine
  • St. John’s wort

  Drugs that May Increase Olaparib Plasma Concentrations

  Strong or moderate inhibitors of CYP3A can increase olaparib plasma concentrations. Concomitant use should be avoided or the dose of olaparib may need to be reduced.

  Anticancer Agents

  Clinical studies indicate a potentiation and prolongation of myelosuppressive toxicity when olaparib is combined with other myelosuppressive anticancer agents, including DNA damaging agents.

  Other Interactions

  Grapefruit and Seville oranges can increase the chance of side effects with olaparib and should be avoided.                                                                                                                                                Several medications should be avoided when taking Olanib (olaparib):

  Strong CYP3A Inducers

  Avoid concomitant use of strong CYP3A inducers as they can significantly decrease olaparib plasma concentrations. Examples include:

  • Phenytoin
  • Rifampicin
  • Carbamazepine
  • St. John’s wort

  Strong or Moderate CYP3A Inhibitors

  Avoid concomitant use of strong or moderate CYP3A inhibitors as they can increase olaparib plasma concentrations. Examples include:

  • Itraconazole, telithromycin, clarithromycin, ketoconazole, voriconazole (strong inhibitors)
  • Amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole (moderate inhibitors)

  If a strong or moderate CYP3A inhibitor must be co-administered, the dose of olaparib may need to be reduced.

  Grapefruit and Seville Oranges

  Grapefruit, grapefruit juice, Seville oranges and Seville orange juice should be avoided during olaparib treatment as they are CYP3A inhibitors.

  Myelosuppressive Anticancer Agents

  Clinical studies indicate a potentiation and prolongation of myelosuppressive toxicity when olaparib is combined with other myelosuppressive anticancer agents, including DNA damaging agents. The recommended olaparib monotherapy dose is not suitable for combination with these agents.

  

  Olaparib

  PARP inhibitor medication for ovarian cancer

  More

  Use

  Maintenance treatment of BRCA-mutated advanced ovarian cancer in adults.

  Mechanism

  Inhibits poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.

  Target Patients

  Cancers in people with hereditary BRCA1 or BRCA2 mutations, including some ovarian, breast, and prostate cancers.

  Based on the provided search results, the key points about the mechanism of action of Olanib (olaparib) are:

  Mechanism of Action

  Inhibition of PARP Enzymes

  • Olaparib is a PARP (Poly (ADP-ribose) polymerase) inhibitor that works by blocking the activity of PARP enzymes 
  • PARP enzymes are involved in repairing single-strand DNA breaks in cells 

  Disruption of DNA Repair

  • By inhibiting PARP, olaparib disrupts the DNA repair process in tumor cells 
  • This leads to the accumulation of DNA damage, particularly double-strand breaks, which are lethal to the rapidly dividing tumor cells 

  Synthetic Lethality in BRCA-Deficient Cells

  • Tumor cells with deficiencies in the BRCA1 or BRCA2 genes, which are involved in homologous recombination DNA repair, are particularly sensitive to PARP inhibition 
  • This is known as “synthetic lethality” – the combination of PARP inhibition and BRCA deficiency is lethal to the tumor cells 
  
  Key Precautions

  Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML)

  • Patients should be monitored for hematological toxicity at baseline and monthly thereafter
  • Discontinue if MDS/AML is confirmed

  Pneumonitis

  • Interrupt treatment if pneumonitis is suspected
  • Discontinue if pneumonitis is confirmed

  Embryo-Fetal Toxicity

  • Olaparib can cause fetal harm
  • Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception

  Hypersensitivity

  • Olaparib is contraindicated in patients with hypersensitivity to the drug or any of its ingredients

  Dietary Restrictions

  Grapefruit and Seville Oranges

  • Grapefruit, grapefruit juice, Seville oranges and Seville orange juice should be avoided during olaparib treatment as they are CYP3A inhibitors

  Alcohol

  • It is advisable to avoid alcohol with Olanib 150 mg as the interactions are still unknown

  key dietary restrictions to be aware of when taking Olanib (olaparib):

  Avoid Grapefruit and Seville Oranges

  • Grapefruit, grapefruit juice, Seville oranges, and Seville orange marmalade should be avoided while taking olaparib.
  • These foods are CYP3A inhibitors, which can increase olaparib plasma concentrations and the risk of side effects.

  Limit Alcohol

  • While the specific interactions between olaparib and alcohol are not fully characterized, it is generally advisable to limit alcohol consumption during olaparib treatment.
  • Alcohol can potentially increase the risk of side effects.

  Maintain a Healthy Diet

  • There are no other specific dietary restrictions mentioned in the search results.
  • However, it is important to maintain a healthy, balanced diet during cancer treatment to support overall health and minimize side effects.

  Dosage

  • Recommended Dose: The recommended dose of Olanib is 300 mg (two 150 mg tablets) taken twice a day, making a total daily dose of 600 mg.
  • Administration: Olanib tablets should be swallowed whole and not chewed, crushed, dissolved, or divided. They can be taken with or without food.

  Storage

  • Storage Conditions: Olanib tablets should be stored at room temperature.

  Reviews

  • Product Information: Olanib is a PARP (poly ADP-ribose polymerase) inhibitor primarily used in the treatment of ovarian, breast, pancreatic, and prostate cancers with specific genetic mutations like BRCA1 and BRCA2.
  • Side Effects: Common side effects include nausea, fatigue, vomiting, anemia, diarrhea, decreased appetite, headache, dysgeusia (altered taste), thrombocytopenia (low platelet count), and neutropenia (low levels of neutrophils).
  • Interactions: Olanib can interact with other medications, particularly those that are CYP3A inhibitors or inducers. Grapefruit and Seville oranges should be avoided as they can increase the risk of side effects.
  • Contraindications: Olanib is contraindicated in patients who are hypersensitive to the drug or any of its ingredients.